STUDY OF PROFILE OF CHRONIC KIDNEY DISEASE RELATED MINERAL BONE DISORDERS IN HEMODIALYSIS PATIENTS- A STUDY FROM RESOURCE LIMITED TERTIARY CARE SETUP

8 Feb 2025 12 a.m. 12 a.m.
WCN25-AB-3373, Poster Board= SAT-062

Introduction:

Majority of Chronic kidney disease (CKD) patients are at an increased risk of developing disturbances of bone and mineral metabolism. These disturbances lead to a constellation of bone lesions which was previously referred to as renal osteodystrophy (ROD), manifesting as bone pain, muscle-tendon rupture, pruritus and high incidence of fractures. Patients with ROD are also predisposed to cardiovascular calcification with associated high morbidity and mortality rates.

The term ROD does not encompass this important extraskeletal manifestation. Therefore, to address these drawbacks and accommodate the extraskeletal manifestations,The KDIGO workgroup recommended a broader term, CKD–mineral and bone disorder (CKD-MBD) for the systemic disorder of mineral and bone metabolism due to CKD and that the term renal osteodystrophy should exclusively be used to describe disorders in bone morphology associated with CKD

CKD-MBD should be defined as:

A systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:

(i)                abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism;

(ii)              abnormalities in bone turnover, mineralization, volume, linear growth, or strength; or

(iii)            vascular or other soft tissue calcification

Several observational studies have shown an association between deranged markers of CKD-MBD and poor clinical outcomes in both predialysis and dialysis patients. For example, elevated levels of phosphate, calcium and PTH have been shown to be associated with cardiovascular-specific mortality in patients with CKD.

Methods:

AIM:

TO STUDY THE PROFILE OF MINERAL BONE DISORDERS IN MAINTENANCE HEMODIALYSIS PATIENTS 

OBJECTIVES :

·        TO EVALUATE THE DISTURBANCES IN MINERAL METABOLISM

·        ABNORMALITIES OF BONE

·        HORMONE ABNORMALITIES

PATIENTS & METHODS

•      STUDY DESIGN –OBSERVATIONAL STUDY

•      SETTING- TERTIARY CARE TEACHING INSTITUTE

STUDY POPULATION

ALL THE PATIENTS ADMITTED TO DEPARTMENT OF NEPHROLOGY – CHRONIC KIDNEY DISEASES ON MAINTENANCE HEMODILAYSIS ,  NAÏVE & OLD.

INCLUSION CRITERIA

•      AGE > 18YEARS

•      ON MAINTENANCE HEMODIALYSIS

•      SYMPTOMATIC PATIENTS

EXCLUSION CRITERIA

•      AGE < 18YEARS

•      OTHER STAGES OF CHRONIC KIDNEY DISEASE

•      ACUTE KIDNEY INJURY

•      USE OF STERIODS

METHODOLOGY

•      DEATILED HISTORY – ONSET OF SYMPTOMS

•      DEMOGRAPHIC PROFILE

•      BIOCHEMICAL PROFILE- CBP/RFT/SE/ALP/CA/PO4/UA

•      VIT D3, i PTH ASSAY

•      USG NECK

•      SKELETAL SURVEY

Categories definition

•      Hypocalcemia (corrected Ca< 8.5mg/dL), Hypercalcemia (corrected Ca>10.5 mg/dL),

•      Hyperphosphatemia (PO4 >4.5 mg/dL), Hypophosphatemia (PO4 <2.5mg/dL),

•      Vitamin D -Deficiency (<10ng/mL), Insufficiency (10- 20 ng/mL) and Sufficiency (>20ng/mL)

•      Hyperparathyroidism was defined as iPTH levels of > 300 pg/ml.

•      Adynamic bone disease in CKD 4 and 5 was defined as iPTH <100pg/Ml

•      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3): 

S1-201.

Results:

CLINICAL PROFILE OF SUBJECTS

 

 

AGE (YEARS) (MEAN ± SD)

 

48.39±14.26

GENDER

MALE:FEMALE

1.3:1

 

MALE

147(42%)

 

FEMALE

182(52%)

ACCESS

AVF

67(19%)

 

IJV

259(74%)

 

PERMCATH

2(0.5%)

HD VINTAGE

<6M

130(37%)

 

6M-2Y

109(31%)

 

2Y-5Y

88(25%)

 

>5Y

2(0.5%)

 

COMORBIDITIES

 

DM

112(32%)

HTN

280(80%)

CAD

1(0.3%)

CVA

56(16%)

DM+HTN

88(25%)

DM+CVA

42(12%)

DM+CAD

7(2%)

HTN+CVA

49(14%)

HTN+CAD

7(1.9%)

DM+HTN+CVA

35(10%)

DM+HTN+CAD

7(1.9%)

DM+HTN+CAD+CVA

3(0.9%)

 

Bio-chemical Profile                 

Mean ± SD

Haemoglobin (gm/dl)

7.9 ± 1.9

TLC cells

9695±4485

Platelets

2.1± 0.8

Urea (mg/dL)

136 ±59

Creatinine (mg/dL)

8.5±4.2

Sodium(mEq/L)

140± 10.3

Potassium(mEq/L)

4.1±1.5

Calcium (mg/dL)

8.0 ± 1.1

Phosphorus (mg/dL)

6.6 ±1.2

Alkaline phosphatase (U/L)

220 ± 65.4

Vit D3(ng/mL)

29.16 ± 11.1

iPTH (pg/mL)

266.3± 220.1

 

 

 

USG NECK

 

findings no of patients %         

     

Adenoma

5

1.3

Hyperplasia

99

28.3

Normal

108

30.9

total

350

100.0

 

SKELETAL SURVEY

 

N

Percent

 

Valid

91 

26.1

 

BROWN TUMOR

2

.7

 

ROD

256

73.3

 

Total

350

100.0

 

 

 

 

i PTH

HB

UREA

CREAT

CA

PO4

UA

ALP

VITD3

i PTH

Pearson Correlation

1

-0.019

-0.01

0.056

-.608**

.588**

.279**

.433**

-.347**

 

P VALUE

 

0.746

0.861

0.33

0.001

0.001

0.001

0.001

0.001

 

N

350

350

350

350

350

350

350

350

350

HB

Pearson Correlation

-0.019

1

-0.03

-.114*

-0.003

-0.044

-0.048

-0.033

0.104

 

P VALU77E

0.746

 

0.6

0.046

0.96

0.447

0.398

0.561

0.069

 

N

350

350

350

350

350

350

350

350

350

UREA

Pearson Correlation

-0.01

-0.03

1

.406**

0.074

-0.042

-.115*

-0.031

-0.011

 

P VALUE

0.861

0.6

 

0.001

0.196

0.462

0.044

0.59

0.852

 

N

350

350

350

350

350

350

350

350

307

CREAT

Pearson Correlation

0.056

-.114*

.406**

1

-0.081

0.08

-0.018

-0.005

-0.072

 

P VALUE

0.33

0.046

0.001

 

0.159

0.163

0.749

0.934

0.209

 

N

350

350

350

350

350

350

350

350

350

CA

Pearson Correlation

-.608**

-0.003

0.074

-0.081

1

-.556**

-.498**

-.330**

.319**

 

P VALUE

0.001

0.96

0.196

0.159

 

0.001

0.001

0.001

0.001

 

N

350

350

350

350

350

350

350

350

350

PO4

Pearson Correlation

.588**

-0.044

-0.042

0.08

-.556**

1

.345**

.286**

-.230**

 

P VALUE

0.001

0.447

0.462

0.163

0.001

 

0.001

0.001

0.001

 

N

350

350

350

350

350

350

350

350

350

UA

Pearson Correlation

.279**

-0.048

-.115*

-0.018

-.498**

.345**

1

.162**

-0.021

 

P VALUE

0.001

0.398

0.044

0.749

0.001

0.001

 

0.005

0.709

 

N

350

350

350

350

350

350

350

350

350

ALP

Pearson Correlation

.433**

-0.033

-0.031

-0.005

-.330**

.286**

.162**

1

-.306**

 

P VALUE

0.001

0.561

0.59

0.934

0.001

0.001

0.005

 

0.001

 

N

350

350

350

350

350

350

350

350

350

VITD3

Pearson Correlation

-.347**

0.104

-0.011

-0.072

.319**

-.230**

-0.021

-.306**

1

 

P VALUE

0.001

0.069

0.852

0.209

0.001

0.001

0.709

0.001

 

 

N

350

350

350

350

350

350

350

350

350

**. Correlation is significant at the 0.01 level (2-tailed).

 

 

 

 

 

 

 

 

 

 

*. Correlation is significant at the 0.05 level (2-tailed).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conclusions:


 

·        iPTH correlates significantly with Calcium, Phosphorous, Uric Acid, Alkaline phosphatase.

·        Ultrasonography abnormalities of parathyroid gland are noted in 29.6%of the study group.

·        Renal osteodystrophy was noted in 73.3% of the study  population , of which Brown tumor was observed in 0.7%.

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.